Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.41 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.41 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12988236 | 0.93 | TPSAB1 (0.49) | HRH3TPSAB1TPSD1TPSG1 | |
| SCHEMBL22875087 | 0.93 | TPSAB1 (0.46) | HRH3TPSAB1TPSD1TPSG1THRB | |
| SCHEMBL22875359 | 0.91 | TPSAB1 (0.45) | HRH3TPSAB1TPSD1TPSG1THRB | |
| SCHEMBL22874719 | 0.87 | EPHX2 (0.39) | HRH3TPSAB1TPSD1TPSG1 | |
| SCHEMBL26228162 | 0.85 | HRH3 (0.36) | GAAHRH3TPSAB1TPSD1TPSG1 | |
| SCHEMBL4762356 | 0.83 | GAA (0.61) | GAATHRBATML3MBTL1 | |
| SCHEMBL12988207 | 0.82 | GPR119 (0.45) | HRH3 | |
| SCHEMBL22875058 | 0.81 | HRH3 (0.36) | GAAHRH3TPSAB1TPSD1TPSG1 | |
| SCHEMBL2603257 | 0.81 | GPR119 (0.44) | GAA | |
| SCHEMBL2603248 | 0.81 | CYP1A2 (0.45) | GAATHRBATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | GAA 1798/4885HRH3 4527/4885TPSAB1 4136/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | GAA 2106/4885HRH3 4292/4885TPSAB1 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.